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Abstract
Background: The free radical/oxidative stress theory of ageing has received considerable attention, but the evidence
on the association of oxidative stress markers with mortality is sparse.
Methods: We measured derivatives of reactive oxygen metabolite (D-ROM) levels as a proxy for the reactive oxygen
species concentration and total thiol levels (TTL) as a proxy for the redox control status in 10,622 men and women
(age range, 45–85 years), from population-based cohorts from Germany, Poland, Czech Republic, and Lithuania, of
whom 1,702 died during follow-up.
Results: Both oxidative stress markers were significantly associated with all-cause mortality independently from
established risk factors (including inflammation) and from each other in all cohorts. Regarding cause-specific mortality,
compared to low D-ROM levels (≤340 Carr U), very high D-ROM levels (>500 Carr U) were strongly associated with both
cardiovascular (relative risk (RR), 5.09; 95 % CI, 2.67–9.69) and cancer mortality (RR, 4.34; 95 % CI, 2.31–8.16). TTL was only
associated with CVD mortality (RR, 1.30; 95 % CI, 1.15–1.48, for one-standard-deviation-decrease). The strength of the
association of TTL with CVD mortality increased with age of the participants (RR for one-standard-deviation-decrease in
those aged 70–85 years was 1.65; 95 % CI, 1.22–2.24).
Conclusions: In these four population-based cohort studies from Central and Eastern Europe, the oxidative stress
serum markers D-ROM and TTL were independently and strongly associated with all-cause and CVD mortality. In
addition, D-ROM levels were also strongly associated with cancer mortality. This study provides epidemiological
evidence supporting the free radical/oxidative stress theory of ageing and suggests that d-ROMs and TTL are useful
oxidative stress markers associated with premature mortality.
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Background
Ageing is a multi-factorial process. Most hypotheses on the
underlying mechanisms of the ageing process involve de-
terioration of the maintenance of homeostatic metabolic,
inflammatory, and/or redox processes in cells and tissues
[1–3]. The free radical/oxidative stress theory of ageing
puts an increased production of reactive oxygen species
(ROS) in the centre of processes that promote cell ageing
[4, 5]. ROS are natural products of mitochondrial energy
synthesis. Oxidative stress occurs when the natural produc-
tion of ROS cannot be balanced by the anti-oxidative cap-
acity of tissues, leading primarily to mitochondrial DNA
damage and dysfunction and higher cell apoptosis rates [4].
A higher apoptosis rate is associated with a higher cell
turnover and a shortening of telomeres, the ends of the
DNA that limit the maximal number of possible mitoses of
mitotic cells [6]. In summary, an accelerated senescence of
cells mediated by increased telomere loss following unbal-
anced ROS production could be one of the pathways in the
multi-factorial process of ageing [7, 8].
The evidence from studies in humans for these hypoth-
eses remains sparse. The main reason is that ROS have a
very short half-life and cannot be directly measured in
plasma or serum samples [9]. Recently, assays have been
developed to measure indirect biomarkers of ROS that are
stable enough to be assessed in stored blood samples. We
have recently reported a pilot study with a small number
of cases (n = 120 deaths) in which derivatives of reactive
oxygen metabolites (d-ROMs) levels and total thiol levels
(TTL) of proteins were independent predictors of all-cause
mortality at older ages [10]. d-ROMs levels are a proxy for
ROS production [11] and TTL are a proxy for the redox
control status of blood. The d-ROMs assay detects hydro-
peroxide metabolites (chemical: R-O-O-H) mainly of lipids,
but also of glycosides, amino acids, and proteins in the
serum sample. Hydroperoxides are a stable class of d-
ROMs that occur after reactions of the hydroxyl radical
(chemical: OH*), a ROS produced mainly as a product of
the respiratory chain reaction in mitochondria. Hydroper-
oxides are being transported from cells to blood vessels to
decrease the oxidative potential of a cell and are therefore
detectable in serum.
The TTL assay detects free thiol groups of the amino
acids cysteine or methionine (chemical: R-S-H), which
can be reversibly oxidized to disulfide bridges (chemical:
R-S-S-R). The most frequent molecules in human blood
with free thiol groups are glutathione, α-lipoic acid, and
members of the thioredoxin protein family. These mole-
cules are able to oppose the propagation phase of the
peroxidation processes by building a plasma antioxidant
barrier against free radicals in order to maintain redox
homeostasis in human plasma [12].
This study investigated the association of d-ROMs levels
and TTL with mortality from all-causes, cardiovascular
disease (CVD), and cancer in an individual participant data
meta-analysis of four large population-based cohort studies
from Central and Eastern Europe. In addition, we also ex-
amined cross-sectional associations of d-ROMs levels and
TTL with established risk factors for mortality.
Methods
Study population
This investigation is based on the HAPIEE cohorts
(Health, Alcohol and Psychosocial factors in Eastern
Europe) from Poland, Czech Republic, and Lithuania
[13], and the 8-year follow-up of the German ESTHER
cohort (German name: “Epidemiologische Studie zu
Chancen der Verhütung, Früherkennung und optimier-
ten Therapie chronischer Erkrankungen in der älteren
Bevölkerung”) [10].
The total HAPIEE study comprises cohorts in four coun-
tries. As it was not possible to export blood samples from
Russia, only three cohorts were included in the current
analysis. Study participants were recruited in six Czech
towns (Havirov/Karvina, Hradec Kralove, Jihlava, Kromeriz,
Liberec, and Usti nad Labem) in 2002–2005 (n = 8,857), in
Krakow, Poland, in 2002–2005 (n = 10,728), and in Kaunas,
Lithuania, in 2006–2008 (n = 7,161). Each cohort consists
of a random sample of men and women, aged 45–75 years
at baseline, stratified by sex and 5-year age groups, selected
from population registers. The overall response rate was
61 % [13]. Data were collected by questionnaire and a short
examination in a clinic during which a fasting venous blood
sample was taken.
The ESTHER study is a population-based cohort of
9,949 adults, aged 50–74 years at baseline, recruited by
their general practitioners (GP) during a routine health
check-up between 2000 and 2002 in the German federal
state Saarland [14]. The current investigation is based on
the 8-year follow-up, conducted between July 2008 and
December 2010, at which study participants were be-
tween 56 and 85 years old. From baseline to 8-year
follow-up, 499 individuals were deceased, 505 individuals
were no longer able to participate due to poor health,
and 680 had declined further participation. From the
remaining 8,265 participants, 6,061 sent back a question-
naire (response rate, 73.4 %) and 4,637 donated a blood
sample in the office of their GP. The GPs of the study
participants also completed a questionnaire about the
health status of the study participants (available for n =
5,997). Furthermore, 3,124 study participants consented
to an additional 3-hour geriatric assessment performed
by study physicians at the participant’s homes.
Variables in ESTHER and HAPIEE studies were har-
monized and oxidative stress markers were measured in
the framework of the Consortium on Health and Ageing:
Network of Cohorts in Europe and the United States
(CHANCES; www.chancesfp7.eu), which has been
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described elsewhere [15, 16]. The studies are conducted
in accordance with the declaration of Helsinki and writ-
ten informed consent was obtained from all study
participants.
Ethics, consent and permissions
The included studies were approved by the respective
local ethics committees (ESTHER: Medical Faculty of
the University of Heidelberg and the Medical Associ-
ation of Saarland; HAPIEE: University College London
(Great Britain), National Institute of Public Health
(Prague, Czech Republic), Jagiellonian University (Kra-
kow, Poland), and Lithuanian University of Health Sci-
ences (Kaunas, Lithuania)). Written informed consent
has been obtained from all participants included in the
analysed studies and the studies are being conducted in
accordance with the Declaration of Helsinki.
Covariate assessment
In the ESTHER and HAPIEE studies, sociodemographic,
lifestyle, and history of disease data were assessed by self-
administered questionnaires. Height and weight were mea-
sured and supplemented by self-reported information in
ESTHER for those study participants who did not consent
to the home visit. In addition to self-reported information,
the history of common chronic diseases was validated in
the ESTHER study by consulting medical records or the
Saarland cancer registry. Renal impairment was defined by
an estimated glomerular filtration rate <60 mL/min/
1.73 m2, calculated with the creatinine-based Chronic Kid-
ney Disease Epidemiology Collaboration equation [17]. In
the ESTHER cohort, serum creatinine concentrations were
assessed with a kinetic Jaffé method on a Cobas 8000 C701
(analyte: CREJ2 3000, Roche). Total cholesterol and high-
density lipoprotein cholesterol (HDL) were assessed in
serum samples by enzymatic chromatography (analytes:
Chol2 2100, HDLC3 450, Roche) and C-reactive protein
(CRP) by immunoturbidimetry on the Cobas 8000 C701
(analyte: CRPL3 500, Roche). In HAPIEE, total and HDL
cholesterol were also assessed with the same assay method-
ology and Roche analytes, but different autoanalyzers were
used (HAPIEE Czech Republic and Lithuania: Roche
Cobas Mira; HAPIEE Poland: Hitachi 917/Modular P). In
addition, in all HAPIEE cohorts, serum creatinine and CRP
were assessed with the same assay methodology as in ES-
THER, but with analytes from a different supplier (Beck-
man-Coulter) and on a different autoanalyzer (LX-20 Pro,
Beckman-Coulter).
Mortality ascertainment
For these analyses, we used follow-up for total mortality
by official country-wide (Czech Republic, Germany),
local (Lithuania), or regional mortality registers (Poland)
until December 31, 2010, in Poland, December 31, 2011,
in Czech Republic and Lithuania, and until July 31,
2014, in Germany. Cause-specific mortality in Germany
was available only for deaths that occurred until April 2,
2013. The registries were complete for all participants
that did not move outside the covered region of the
registry. Loss to follow-up due to migration was 4 % in
the HAPIEE cohorts (combined) and 2 % in the ES-
THER study. All deaths coded with ICD-10 codes I00-
I99 were considered cardiovascular deaths and cancer
deaths were defined by the ICD-10 codes C00-C97.
Oxidative stress serum marker measurement
The assays used to measure d-ROMs levels (Diacron,
Grosseto, Italy) and TTL (Rel Assay Diagnostics, Gazi-
antep, Turkey) were adapted to an autoanalyzer (LX20-
Pro, Beckman-Coulter, Woerden, The Netherlands) at
the Laboratory for Health Protection Research (Biltho-
ven, The Netherlands), as described previously [18]. The
d-ROMs assay measures the hydroperoxide concentra-
tion in Carratelli Units (Carr U), named after the in-
ventor of the assay, Mauro Carratelli. Each Carr U
corresponds to 0.08 mg hydrogen peroxide (H2O2)/
100 mL in the sample [19]. The TTL assay measures the
concentration of free thiol groups in the sample in
μmol/L.
Measurements were performed in serum samples that
had been stored for approximately 3–10 years in
freezers with –80 °C. d-ROMs and TTL have a good
long-term stability under these conditions [18, 20]. In
the ESTHER 8-year follow-up, d-ROMs and TTL were
measured in all participants that donated blood samples
at their GP’s offices (n = 4,637). However, measure-
ments were conducted at two different time-points be-
cause funding was not available to measure all samples
in the pilot study conducted in June 2012 [10]. To cor-
rect for potential shifts in the assays, 80 samples of
time-point 1 (June 2012) were measured again at time-
point 2 (September 2014) and linear regression equa-
tions were obtained and used to standardize the results
from time-point 2 to the levels of time-point 1, when
the measurements in the HAPIEE cohorts also took
place (throughout the year 2012). Agreement of d-
ROMs measurements was high (Spearman correlation
coefficient r = 0.92 and difference of means = 15 Carr
U) and therefore no corrections were applied. For TTL,
an obvious shift in the assay results (r = 0.88 and differ-
ence of means = 81 μmol/L) was corrected by applying
the following equation to all measurements of time-
point 2: TTLtime-point2 = 0.746 × TTLtime-point1. Further-
more, we excluded 610 measurements in blood samples
that did not fulfil strict haemolytic, icteric and lipemic
quality criteria in the ESTHER study, leaving 4,027 for
analysis in the present study. In the HAPIEE cohorts,
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the number of samples that did not fulfil these quality
criteria was negligible.
Analytical study sample
Because of limited funding, d-ROMs levels and TTL
were not measured in all participants in the HAPIEE
cohorts; instead, a matched case control design was
adopted (Additional file 1: Figure S1). Cases were
defined as all subjects that died during follow-up (n =
1,433) or experienced incident non-fatal myocardial in-
farction (MI) or stroke (n = 658). Controls (n = 4,396)
were frequency matched to cases by sex and 5-year age
groups. To correct the oversampling for MI and stroke
in this mortality analysis, subjects with non-fatal MI or
non-fatal stroke during follow-up were excluded from
the cases in a first step. In order to add a representative
sample of subjects with non-fatal incident MI or stroke
events to the controls, in a second step, the observed
proportion of non-fatal incident MI or stroke events in
each age- and sex-specific stratum in the total cohort
was calculated. In a third step, these proportions were
multiplied by the sample sizes in each stratum in the con-
trols with measured oxidative stress markers. In a fourth
step, the resulting numbers were randomly selected in
each stratum from the group of subjects with non-fatal in-
cident MI or stroke and added to the controls, resulting in
a pool of 4,552 eligible controls for the 1,433 deaths. In
the final step, the pool of eligible controls was used to in-
dividually match exactly two controls to each death by co-
hort, sex, and age (±5 years).
Statistical analyses
Differences in baseline characteristics between cases (death
during follow-up) and controls were assessed with the χ2
test for categorical variables and the Wilcoxon rank-sum
test for continuous variables. Cross-sectional associations
of established risk factors for mortality with high oxidative
stress levels were assessed with logistic regression models
comprising all baseline characteristics modelled as categor-
ical variables (Table 1). The dependent variable “high oxi-
dative stress” was defined by two different definitions
based on d-ROMs levels or TTL. For d-ROMs, according
to the manufacturer’s instructions, a clinical cut-off of >400
Carr U was employed, which classified 23 % of the ES-
THER cohort and 30 % of eligible controls of the HAPIEE
cohort in the “high” oxidative stress category. For TTL, no
clinical cut-offs are available and, as the assay is not yet
standardized, population means varied strongly between
cohorts. Therefore, to match the proportion of individuals
with high oxidative stress obtained by the definition based
on d-ROMs levels, the bottom cohort specific TTL quartile
(25 %) was used to classify subjects to a high oxidative
stress category based on TTL. The cross-sectional
analyses were conducted in all subjects and separately
for women and men.
For longitudinal analyses, Cox proportional hazard
regression (ESTHER cohort) and conditional logistic
regression (HAPIEE matched case–control study) were
utilized to estimate hazard ratios and odds ratios, respect-
ively, for an increase in d-ROMs levels and decrease in
TTL by one cohort-specific standard deviation (SD). In
addition, d-ROMs levels were also modelled as a categor-
ical variable, with manufacturer-recommended clinical
cut-offs for moderate (341–400 Carr U), high (401–500
Carr U) and very high oxidative stress (>500 Carr U) with
reference to subjects with not increased or low oxidative
stress (≤340 Carr U). When the absolute risk is low, logis-
tic and Cox regression usually produce similar results and
the odds ratio can be regarded as an approximation of the
more accurate hazard ratio. We used the term relative risk
(RR) for both effect estimates. In sensitivity analysis, ana-
lyses on cause-specific mortality in the ESTHER cohort
were carried out considering the competing risk of death
due to other causes by fitting a proportional subdistribu-
tion hazards regression model with weights for subjects
that underwent the competing risk event according to an
extension of the Fine and Gray method [21]. However, re-
sults were almost identical with traditional Cox propor-
tional hazard regression and therefore only the latter
results are shown in this manuscript.
Analyses were conducted separately for each cohort and
pooled by meta-analysis with Mantel-Haenszel weighting
and random effects [22], taking the sample size of the co-
horts and the possibility of statistical heterogeneity among
the studies into account. The latter was examined with
Cochrane’s Q test and the I2 statistic.
The following outcomes were analysed: mortality from
all-causes, CVD, cancer and non-CVD, non-cancer causes.
For each outcome, four statistical models were developed,
with an increasing inclusion of established mortality risk
factors into the models. Both d-ROMs levels and TTL
were always included in the same model because their cor-
relation was low (r <0.08 in each cohort). In model 1, ad-
justment was made for age and sex in the ESTHER cohort,
whereas this was not necessary for the HAPIEE cohorts
because cases were individually matched to two controls
by age and sex and analysed in stratified analysis in which
the strata consist of the collection of matched sets. Model
2 additionally adjusted for education, body mass index
(BMI), smoking, alcohol consumption and physical activity.
Model 3 also included diseases that could potentially medi-
ate the association of oxidative stress with mortality (i.e.
dyslipidaemia (assessed by total and HDL cholesterol),
renal impairment, a history of diabetes, hypertension, MI,
stroke, and cancer). Finally, model 4 was additionally ad-
justed for CRP levels, which were strongly correlated with
d-ROMs levels (r = 0.34–0.41 in the cohorts) and, less
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Table 1 Baseline characteristics of study participants by cohort and case status (death during follow-up) and number of cases for cause-specific mortality analyses by cohort
Baseline characteristics HAPIEE Poland HAPIEE Czech Republic HAPIEE Lithuania ESTHER Germany
Cases (Deaths) Eligible controls Cases (Deaths) Eligible controls Cases (Deaths) Eligible controls Cases (Deaths) Controls
Total sample size 525 1498 518 1776 390 1278 269 3,758
Age (years) 62.9 (56.7; 67.0)* 62.1 (55.8; 66.5) 63.6 (58.6; 67.4) 63.0 (57.9; 66.8) 66.5 (61.1; 70.3) 66.1 (60.5; 70.1) 74.1 (70.0; 78.1)* 69.2 (64.3; 74.0)
45 to <60 190 (36.2) 594 (39.7) 154 (29.7) 559 (31.5) 79 (20.3) 292 (22.9) 10 (3.7)* 345 (9.2)
60 to <65 126 (24.0) 355 (23.7) 144 (27.8) 518 (29.2) 83 (21.3) 265 (20.7) 18 (6.9)* 681 (18.1)
65 to <70 198 (37.7) 507 (33.9) 198 (38.2) 634 (35.7) 124 (31.8) 391 (30.6) 42 (15.6)* 1020 (27.1)
70 to <85 11 (2.1) 42 (2.8) 22 (4.3) 65 (3.7) 104 (26.7) 330 (25.8) 199 (74.0)* 1712 (45.6)
Male sex 357 (68.0) 1015 (67.8) 339 (65.4) 1170 (65.9) 261 (66.9) 830 (65.0) 158 (58.7)* 1636 (43.5)
Education
Low 90 (17.2)* 168 (11.2) 90 (17.5)* 175 (10.0) 68 (17.8)* 130 (10.3) 192 (73.3) 2633 (71.1)
Medium 322 (61.5)* 842 (56.2) 377 (73.5)* 1296 (73.7) 181 (47.4)* 463 (36.6) 59 (22.5) 852 (23.0)
High 112 (21.4)* 488 (32.5) 46 (9.0)* 287 (16.3) 133 (34.8)* 672 (53.1) 11 (4.2) 218 (5.9)
BMI (kg/m2) 27.4 (24.5; 30.9) 27.9 (25.1; 30.7) 28.7 (25.7; 32.0)* 28.0 (25.5; 30.9) 28.5 (25.4; 32.8) 29.0 (25.7; 32.1) 28.3 (24.9; 31.2) 27.8 (25.1; 30.9)
<20 13 (2.5) 24 (1.6) 10 (1.9)* 20 (1.1) 11 (2.8)* 10 (0.8) 5 (2.0) 47 (1.3)
20 to <25 130 (24.9) 330 (22.1) 92 (17.8)* 344 (19.4) 74 (19.0)* 236 (18.5) 60 (23.4) 857 (23.2)
25 to <30 222 (42.5) 682 (45.6) 207 (40.0)* 827 (46.6) 154 (39.5)* 516 (40.4) 112 (43.6) 1625 (44.0)
30 to <35 110 (21.1) 362 (24.2) 149 (28.8)* 450 (25.4) 98 (25.1)* 369 (28.9) 52 (20.2) 859 (23.3)
≥35 47 (9.0) 98 (6.6) 60 (11.6)* 134 (7.6) 53 (13.6)* 147 (11.5) 28 (10.9) 304 (8.2)
Smoking
Never 124 (23.8)* 598 (40.0) 140 (27.5)* 761 (43.6) 176 (46.2) * 742 (58.7) 100 (38.8)* 2119 (57.3)
Former 175 (33.5)* 510 (34.1) 192 (37.6)* 598 (34.3) 99 (26.0) * 295 (23.3) 123 (47.7)* 1310 (35.4)
Current 223 (42.7)* 386 (25.8) 178 (34.9)* 386 (22.1) 106 (27.8) * 227 (18.0) 35 (13.6)* 271 (7.3)
Alcohol consumption (g/day) 0 (0; 11.4)* 0 (0; 25.4) 11.4 (2.7; 31.9)* 14.3 (5.7; 30.3) 0 (0; 8) 1.4 (0; 10.3) 3.4 (0; 13.5)* 6.7 (0; 14.4)
Vigorous physical activity 331 (67.8)* 1078 (75.4) 298 (60.8)* 1295 (74.7) 176 (46.4)* 742 (58.7) 87 (41.6)* 2067 (62.4)
Total cholesterol (mg/dL) 218 (192; 251) 219 (195; 247) 213 (186; 239)* 218 (194; 247) 220 (190; 251)* 225 (200; 255) 211 (180; 249)* 233 (202; 265)
<200 180 (34.3) 443 (29.7) 206 (39.9)* 550 (31.0) 124 (31.8)* 323 (25.4) 102 (38.1)* 868 (23.1)
200 to <280 297 (56.6) 930 (62.1) 272 (52.6)* 1088 (61.3) 230 (59.0)* 801 (62.9) 135 (50.4)* 2278 (60.7)
≥280 48 (9.1) 125 (8.3) 39 (7.5)* 138 (7.8) 36 (9.2)* 149 (11.7) 31 (11.6)* 609 (16.2)
HDL cholesterol (mg/dL) 51 (42; 61)* 52 (44; 61) 48 (40; 58)* 49 (41; 60) 53 (43; 63)* 54 (46; 65) 54 (45; 64)* 59 (49; 70)
<40 97 (18.5)* 187 (12.5) 132 (25.5) 369 (20.9) 72 (19.0)* 133 (10.6) 38 (14.2)* 221 (5.9)
40 to <80 392 (74.7)* 1237 (82.6) 359 (69.4) 1313 (74.3) 280 (73.7)* 1024 (81.7) 207 (77.2)* 3098 (82.5)
≥80 36 (6.9)* 74 (4.9) 26 (5.0) 86 (4.9) 28 (7.4)* 96 (7.7) 23 (8.6)* 436 (11.6)
CRP (mg/L) 2.6 (1.1; 5.6)* 1.7 (0.8; 3.1) 2.7 (1.12; 5.6)* 1.9 (0.9; 3.6) 2.7 (1.2; 5.6)* 1.6 (0.8; 3.2) 2.8 (1.3; 6.2)* 1.8 (0.9; 3.7)
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Table 1 Baseline characteristics of study participants by cohort and case status (death during follow-up) and number of cases for cause-specific mortality analyses by cohort
(Continued)
≤3 294 (56.0)* 1100 (73.4) 281 (54.3)* 1218 (68.6) 214 (54.9)* 931 (72.9) 143 (53.2)* 2567 (68.3)
>3 to ≤10 165 (31.4)* 328 (21.9) 185 (35.7)* 474 (26.7) 125 (32.1)* 276 (21.6) 96 (35.7)* 967 (25.7)
>10 66 (12.6)* 70 (4.7) 52 (10.0)* 84 (4.7) 51 (13.1)* 71 (5.6) 30 (11.2)* 224 (6.0)
eGFR (mL/min/1.73 m2) 89.2 (76.1; 97.5) 88.6 (77.7; 95.7) 78.2 (64.9; 90.4)* 80.1 (69.3; 90.6) 85.0 (70.0; 93.4) 86.5 (74.1; 94.2) 63.9 (51.8; 76.9)* 71.8 (62.7; 80.7)
≥60 487 (92.7)* 1440 (96.1) 426 (82.2)* 1600 (90.1) 336 (86.2)* 1184 (92.6) 163 (60.6)* 3001 (80.0)
<60 38 (7.2)* 58 (3.9) 92 (17.8)* 176 (9.9) 54 (13.9)* 94 (7.4) 106 (39.4)* 757 (20.1)
History of hypertension 323 (61.9)* 837 (55.9) 300 (58.6)* 902 (50.9) 248 (65.1) 788 (62.4) 221 (82.2)* 2637 (70.2)
History of diabetes 111 (21.2)* 207 (13.8) 123 (24.0)* 243 (13.7) 56 (14.7)* 91 (7.2) 108 (40.2)* 892 (23.7)
History of MI 110 (21.1)* 147 (9.9) 69 (14.1)* 104 (6.1) 71 (18.6)* 121 (9.6) 50 (18.6)* 217 (5.8)
History of stroke 31 (6.0)* 33 (2.2) 40 (8.2)* 59 (3.5) 35 (9.2)* 68 (5.4) 46 (17.1)* 262 (7.0)
History of cancer 52 (9.9)* 67 (4.5) 53 (10.2)* 93 (5.2) 58 (14.9)* 104 (8.1) 94 (34.9)* 428 (11.4)
d-ROMs (Carr U) 368 (324; 425)* 349 (309; 394) 404 (350; 470)* 381 (335; 439) 372 (330; 421)* 356 (317; 393) 369 (320; 406)* 350 (305; 395)
≤340 178 (33.9)* 650 (43.4) 102 (19.7)* 483 (27.2) 123 (31.5)* 498 (39.0) 96 (35.7)* 1649 (43.9)
341–400 167 (31.8)* 514 (34.1) 146 (28.2)* 564 (31.8) 138 (35.4)* 500 (39.1) 94 (34.9)* 1250 (33.3)
401–500 143 (27.2)* 314 (21.0) 185 (35.7)* 561 (31.6) 101 (25.9)* 258 (20.2) 70 (26.0)* 789 (21.0)
>500 37 (7.0)* 20 (1.3) 85 (16.4)* 168 (9.5) 28 (7.2)* 22 (1.7) 9 (3.3)* 70 (1.9)
TTL (μmol/L) 509 (445; 566)* 518 (464; 570) 406 (363; 452) 411 (371; 450) 313 (273; 357)* 321 (283; 359) 303 (239; 356) * 335 (284; 383)
Cause of death
CVD 165 (32.0) n.a. 189 (36.6) n.a. 155 (39.7) n.a. 51 (31.7) n.a.
Cancer 235 (45.5) n.a. 235 (45.5) n.a. 158 (40.5) n.a. 74 (46.0) n.a.
Non-CVD, non-cancer 116 (22.5) n.a. 93 (18.0) n.a. 77 (19.7) n.a. 36 (22.4) n.a.
Unknown 9 (n.a.) n.a. 1 (n.a.) n.a. 0 (n.a.) n.a. 108 (n.a.)a n.a.
Unless indicated otherwise, the table shows proportions (%) for categorical and medians (25th; 75th percentile) for continuous variables. Numbers shown were drawn from the not imputed data set. Therefore, numbers
do not always add up to the total because of missing values (see Additional file 1: Table S1 for proportion of missing values for each variable)
*Statistically significant (P <0.05) difference among cases and controls assessed by χ2 test for categorical and Wilcoxon rank sum test for continuous variables
BMI, Body mass index; CRP, C-reactive protein; CVD, Cardiovascular disease; d-ROMs, Derivatives of reactive oxygen metabolites; eGFR, Estimated glomerular filtration rate; HDL, High-density lipoprotein; MI, Myocardial
infarction; n.a., Not applicable; TTL, Total thiol levels
aInformation on cause of death is released by German authorities later than general mortality information. At the time of the analysis, information about all-cause mortality was available until July 31, 2014, and information
about causes of deaths for deaths that occurred until April 2, 2013
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strongly, with TTL (r = 0.11–0.17 in the cohorts). Age was
modelled as a continuous variable and all other variables
were modelled as categorical variables (categories are
shown in Table 1). We tested for interactions between d-
ROMs/TTL with covariates by adding appropriate inter-
action terms to model 2.
Subgroups to be analysed were chosen a priori with the
aim to stratify for the most important potential determi-
nants of high oxidative stress levels: cohort/country, age,
sex, history of MI or cancer, and inflammatory status. Be-
cause of sample size limitations, stratified analyses were
restricted to mortality of all causes, CVD, and cancer. To
address the possibility of reverse causation bias [23], ana-
lyses were conducted separately for events that occurred
in years 1–2, years 3–4, and years 5–6 of follow-up. Be-
cause of sample size limitations, this stratified analysis
could only be performed for all-cause mortality. To avoid
model instability, a cohort-specific subgroup analysis re-
sult was only considered for meta-analysis when at least
25 events occurred in the sub-group.
Multiple imputation was employed to impute the
number of missing baseline covariate values shown in
Additional file 1: Table S1. The proportion of missing
values was below 5 % for all variables with the exception
of alcohol consumption and physical activity, which had
up to 22 % of missing values. To the best of our know-
ledge, data were missing at random, which is the assump-
tion of the multiple imputation. Separately by cohort, case
status and sex, 20 complete data sets were imputed with
the SAS 9.3 procedure “PROC MI”, using the Markov
chain Monte Carlo method. Variables from the “full”
model were used for the imputation model. All multivari-
able analyses were performed in the 20 imputed data sets
and results of the individual data sets were combined by
the SAS 9.3 procedure “PROC MIANALYZE”.
The meta-analyses were conducted with the statistical
software Comprehensive Meta-Analysis 2.0 (Biostat,
Englewood, NJ, USA). All other analyses were con-
ducted with SAS, version 9.2 (Cary, North Carolina,
USA). All statistical tests were two-sided, using an
alpha level of 0.05.
Results
Comparison of baseline characteristics of the analysed
cohorts and of cases and controls
Baseline characteristics of cases and controls in the four
cohorts are shown in Table 1. The HAPIEE cohorts in-
cluded approximately two thirds of men and one third
of women among cases and controls (because of the
sampling, see Additional file 1: Figure S1), whereas more
men were among the cases and more women among the
controls in the ESTHER study. Because of the sampling
of subjects in the HAPIEE cohorts, the age distribution
among cases and controls was comparable, whereas
cases were much older than controls in the ESTHER
study. Controls from the ESTHER study were on average
7.1, 6.2, and 3.1 years older than controls from the HAP-
IEE Poland, Czech Republic, and Lithuania studies, re-
spectively. Comparing only cases with cases and controls
with controls in the different cohorts, most baseline
characteristics were comparably distributed among the
cohorts, with few exceptions that could mostly be ex-
plained by the age differences of the cohorts. Differences
observed for years of school education could be ex-
plained by the different educational systems of the coun-
tries and different years of school enrolment of study
participants. The higher prevalence of diabetes in the
ESTHER study is due to the fact that ESTHER study
participants were screened for undetected diabetes at
baseline, which was not done in the HAPIEE cohorts.
With regards to the oxidative stress markers, median d-
ROMs levels were similar in HAPIEE Lithuania, HAP-
IEE Poland and ESTHER, and higher in HAPIEE Czech
Republic than in the other three cohorts. Differences in
TTL were much more pronounced than those of d-
ROMs levels and mirror the age differences of the co-
horts. The causes of deaths were similarly distributed
among cases from the cohorts, with roughly 35 % being
CVD deaths, 45 % cancer deaths, and 20 % deaths from
other causes. All the assessed established risk factors for
mortality were found to be statistically significantly asso-
ciated with this outcome in the majority of the analysed
studies (Table 1).
Cross-sectional associations of established risk factors for
mortality and high oxidative stress levels
Associations between high oxidative stress levels (defined
as d-ROMs levels >400 Carr U or bottom cohort-specific
TTL quartile) were similar in the ESTHER cohort, HAP-
IEE cases, and HAPIEE controls, with low heterogeneity
between studies (Additional file 1: Tables S2-S3). In the
meta-analyses, female sex and increasing CRP levels were
associated with higher odds for both definitions of high
oxidative stress (Table 2), whereas alcohol consumption,
physical activity, and a history of diabetes or stroke were
not associated with both definitions. However, high
oxidative stress defined by d-ROMs was associated with
smoking, increasing total cholesterol, increasing HDL
cholesterol, and a history of hypertension, MI or cancer,
whereas high oxidative stress by TTL was not associated
with these factors. Conversely, high oxidative stress de-
fined by TTL was associated with increasing age, increas-
ing education, increasing BMI, and renal impairment,
whereas high oxidative stress defined by d-ROMs levels
was not associated with these factors. The unexpected dir-
ection of the association of BMI and increased d-ROMs
levels was introduced by one outlier (cases of HAPIEE
Lithuania study) and adjustment for diseases and CRP. In
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the meta-analysis of results from the main model 2 and
exclusion of cases from HAPIEE Lithuania, overweight
and adiposity grade I (BMI, 30 to <35 kg/m2) were not as-
sociated with high oxidative stress defined by d-ROMs
levels and adiposity grade II–III (BMI, ≥35 kg/m2) was
statistically significantly associated with increased d-
ROMs (Additional file 1: Table S4), i.e. the same direction
as observed for high oxidative stress defined by TTL.
Similarly, the other paradox directions of risk factors
with oxidative stress (increasing HDL with high oxida-
tive stress by d- ROMs and increasing education with
high oxidative stress by TTL) were not observed in
models that were only adjusted for age and sex (Add-
itional file 1: Tables S4,S5).
A strongly decreased odds of males compared to females
for high oxidative stress by both definitions was observed
in all models and was stronger for d-ROMs levels than
TTL (Additional file 1: Table S6). However, the cross-sec-
tional associations of baseline characteristics with high
oxidative stress were similar in men and women (Add-
itional file 1: Tables S7,S8). Consistent sex differences
were found only for current smoking and CRP, which
showed a stronger association with high oxidative stress
levels (defined by d-ROMs levels) in men than in
women (Additional file 1: Table S7) and for high age
(70–85 years), which was more strongly associated with
high oxidative stress levels (defined by TTL) in women
than in men (Additional file 1: Table S8).
Longitudinal association of oxidative stress markers with
mortality outcomes
The HAPIEE Poland, Czech Republic, Lithuania, and
ESTHER cohorts were followed-up for mortality for a
median of 7.1, 8.1, 4.6, and 5.0 years, respectively. Dur-
ing the follow-up, 525, 518, 390, and 269 study partici-
pants in the respective cohorts died. From the 1,702
deaths in total, 560 were of cardiovascular and 702 of
cancer origin.
d-ROMs levels and TTL were statistically significantly
associated with all-cause mortality in all models, with
stronger effect estimates for d-ROMs levels than for
TTL (Table 3). Although the strength of the associations
declined with increasing adjustment for other factors, a
1.3-fold increased mortality for high oxidative stress
levels (d-ROMs levels: 401–500 Carr U) and a 2.3-fold
increased mortality for very high oxidative stress levels
(d-ROMs levels >500 Carr U) remained statistically sig-
nificant in the fully adjusted model 4. Compared to the
results for all-cause mortality, results for d-ROMs levels
were stronger for CVD mortality, similar for cancer
mortality and weaker for non-CVD, non-cancer mortal-
ity. Effect estimates for a decrease in TTL by one SD
with CVD mortality and non-CVD, non-cancer mortality
were comparable to the effect estimates observed for an
increase of d-ROMs levels by one SD. However, TTL
were not associated with cancer mortality in any model
and not statistically significantly associated with non-
CVD, non-cancer mortality in models 3 and 4.
Additive risks by d-ROMs levels and TTL
No statistically significant interactions were observed
between d-ROMs levels and TTL and between the two
oxidative stress markers and other risk factors. How-
ever, d-ROMs levels and TTL had additive predictive
values for CVD mortality (Table 4). Subjects with high
oxidative stress by both definitions had the highest RR
for CVD mortality (RR, 2.47; 95 % CI, 1.58–3.98) with
about twice the excess risk of subjects with high
Table 2 Cross-sectional associations of established risk factors
for mortality and high oxidative stress levels defined by derivatives
of reactive oxygen metabolites (d-ROMs) levels or total thiol levels
(TTL)
Risk factors for mortality Odds of high oxidative
stress by
d-ROMsa TTLb
Increasing age – ↑
Male sex ↓ ↓
Decreasing education – (↓)c
Increasing BMI (↓)d ↑
Former smoking ↑ –
Current smoking ↑ –
No alcohol consumption – –
High alcohol consumptione – –
No performance of vigorous physical activity – –
Increasing total cholesterol ↑ –
Decreasing HDL cholesterol (↓)f –
Increasing CRP ↑ ↑
Renal impairmentg – ↑
History of hypertension ↑ –
History of diabetes – –
History of MI ↑ –
History of stroke – –
History of cancer ↑ –
ad-ROMs >400 Carr U
bLowest quartile of TTL in the different cohorts, i.e. ESTHER <281.57 μmol/L;
HAPIEE Poland cases and eligible controls <464 μmol/L; HAPIEE Czech
Republic cases and eligible controls <371 μmol/L; HAPIEE Lithuania cases and
eligible controls <283 μmol/L
cNo association in age- and sex-adjusted model (Additional file 1: Table S4)
dNo association in main model for all BMI categories with exception of the
highest BMI category, which showed a statistically significantly increased odds
for high oxidative stress (Additional file 1: Table S3)
eDefinition of high alcohol consumption: women ≥20 and men ≥40 g ethanol
per day
fNo association in main model (Additional file 1: Table S3)
gEstimated glomerular filtration rate <60 mL/min/1.73 m2
BMI, Body mass index; CRP, C-reactive protein; HDL, High-density lipoprotein;
MI, Myocardial infarction; d-ROMs, Derivatives of reactive oxygen metabolites;
TTL, Total thiol levels
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oxidative stress defined by only d-ROMs levels (147 %
excess risk compared to 72 % excess risk). Agreement
of the two definitions of high oxidative stress was rela-
tively low and only 7 % of the ESTHER population and
9 % of eligible controls of the HAPIEE cohorts fulfilled
both definitions.
Subgroup analyses
Table 5 shows the associations of TTL and d-ROMs
levels with all-cause, CVD and cancer mortality stratified
by cohort/country, age, sex, history of MI or cancer,
inflammatory status and time-point of event during
follow-up. With respect to cohort/country, results for d-
ROMs levels were homogenous and statistically signifi-
cant in all cohorts/countries, with few exceptions (non-
significant association with CVD mortality in ESTHER
and with cancer mortality in HAPIEE Poland). For TTL,
there was a tendency towards stronger effect estimates
in the older cohorts (HAPIEE Lithuania and ESTHER)
than in the younger cohorts (HAPIEE Poland and Czech
Republic). This age difference for TTL was also observed
when analyses were stratified by age groups. The
Table 3 Associations of derivatives of reactive oxygen metabolites (d-ROMs) levels and total thiol levels (TTL) with all-cause and
disease-specific mortality
Outcome Oxidative stress
marker
Modelling ncases Model 1 Model 2 Model 3 Model 4
RR (95 % CI)a RR (95 % CI)b RR (95 % CI)c RR (95 % CI)d
All-cause mortality d-ROMs ≤340 Carr U 499 Ref Ref Ref Ref
341–400 Carr U 545 1.27 (1.07–1.51)* 1.21 (1.04–1.40)* 1.20 (1.03–1.40)* 1.13 (0.96–1.32)
401–500 Carr U 499 1.86 (1.58–2.17)* 1.60 (1.35–1.89)* 1.53 (1.29–1.83)* 1.32 (1.10–1.59)*
>500 Carr U 159 4.48 (2.87–7.00)* 3.79 (2.08–6.90)* 2.99 (1.62–5.52)* 2.30 (1.40–3.77)*
d-ROMs Increase per 1 SDe 1702 1.44 (1.35–1.53)* 1.34 (1.25–1.43)* 1.28 (1.19–1.36)* 1.20 (1.12–1.29)*
TTL Decrease per 1 SDf 1702 1.17 (1.04–1.33)* 1.19 (1.07–1.32)* 1.14 (1.06–1.23)* 1.12 (1.04–1.21)*
CVD mortality d-ROMs ≤340 Carr U 157 Ref Ref Ref Ref
341–400 Carr U 178 1.29 (1.00–1.67)* 1.28 (0.97–1.70) 1.28 (0.89–1.82) 1.14 (0.83–1.56)
401–500 Carr U 171 1.71 (1.32–2.22)* 1.78 (1.31–2.43)* 1.81 (1.28–2.54)* 1.49 (1.04–2.13)*
>500 Carr Ug 54 5.16 (2.35–11.31)* 5.09 (2.67–9.69)* 4.86 (2.38–9.95)* 4.34 (2.06–9.15)*
d-ROMs Increase per 1 SDe 560 1.53 (1.35–1.72)* 1.44 (1.27–1.64)* 1.37 (1.19–1.58)* 1.30 (1.12–1.51)*
TTL Decrease per 1 SDf 560 1.31 (1.17–1.47)* 1.30 (1.15–1.48)* 1.27 (1.10–1.47)* 1.25 (1.09–1.45)*
Cancer mortality d-ROMs ≤340 Carr U 198 Ref Ref Ref Ref
341–400 Carr U 224 1.27 (1.01–1.61)* 1.18 (0.92–1.51) 1.17 (0.91–1.52) 1.08 (0.83–1.41)
401–500 Carr U 200 1.71 (1.32–2.21)* 1.48 (1.12–2.75)* 1.41 (1.05–1.89)* 1.16 (0.85–1.57)
>500 Carr U 80 5.29 (3.16–8.85)* 4.34 (2.31–8.16)* 3.82 (1.79–8.18)* 2.50 (1.31–4.78)*
d-ROMs Increase per 1 SDe 702 1.42 (1.29–1.56)* 1.35 (1.20–1.52)* 1.30 (1.14–1.47)* 1.19 (1.05–1.35)*
TTL Decrease per 1 SDf 702 1.05 (0.92–1.19) 1.07 (0.96–1.19) 1.01 (0.90–1.13) 0.98 (0.87–1.09)
Non-CVD, non-cancer
mortality
d-ROMs ≤340 Carr U 103 Ref Ref Ref Ref
341–400 Carr U 99 1.15 (0.80–1.67) 0.94 (0.52–1.68) 0.97 (0.51–1.82) 0.85 (0.48–1.49)
401–500 Carr U 99 2.14 (1.51–3.05)* 1.49 (0.91–2.45) 1.51 (0.89–2.55) 1.16 (0.67–2.01)
>500 Carr U 21 3.32 (1.68–6.59)* 1.98 (0.94–4.15) 1.93 (0.83–4.45) 1.56 (0.69–3.53)
d-ROMs Increase per 1 SDe 322 1.41 (1.22–1.63)* 1.26 (1.08–1.47)* 1.27 (1.07–1.51)* 1.15 (0.96–1.37)
TTL Decrease per 1 SDf 322 1.23 (1.07–1.42)* 1.27 (1.02–1.60)* 1.19 (0.94–1.48) 1.15 (0.93–1.43)
*Statistically significant (P <0.05)
aAdjusted for age and sex in the ESTHER cohort, whereas this was not necessary for the HAPIEE cohorts because cases were individually matched to two controls
by age and sex and analysed in stratified analysis in which the strata consist of the collection of matched sets. In addition, the other oxidative stress marker
(i.e. TTL or d-ROMs) was included in this model
bVariables of model 1 and education, BMI, smoking, alcohol consumption, and vigorous physical activity
c Variables of model 2 and total cholesterol, HDL cholesterol, renal impairment, history of diabetes, history of hypertension, history of myocardial infarction, history
of stroke, and history of cancer
dVariables of model 3 and CRP
e1 SD of d-ROMs levels equal 81.1, 89.6, 70.5, and 71.9 Carr U in the HAPIEE Poland, Czech Republic, Lithuania, and ESTHER studies, respectively
f1 SD of TTL equals 79.5, 69.1, 74.1, and 75.3 μmol/L in the HAPIEE Poland, Czech Republic, Lithuania, and ESTHER studies, respectively
gMeta-analyses without the ESTHER study because no events were observed in this category in this study
CVD, Cardiovascular disease; CI, Confidence interval; d-ROMs, Derivatives of reactive oxygen metabolites; ncases, Incident case numbers; Ref, Reference category;
SD, Standard deviation; TTL, Total thiol levels
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strongest effect estimates for all-cause and CVD mortal-
ity were observed in the oldest age group (70–85 years).
Conversely, there was no clear age trend for d-ROMs.
However, d-ROMs levels were not statistically signifi-
cantly associated with CVD mortality in the oldest age
group and not with cancer mortality in the youngest age
group (45 to <60 years).
We did not find strong sex differences, but the associ-
ations of d-ROMs levels with mortality outcomes had a
tendency towards slightly stronger results in men than
in women. Furthermore, there was a tendency towards
stronger results for d-ROMs levels in subjects with a
history of MI or with a history of cancer but effect esti-
mates were also statistically significant in subjects with-
out a history of these diseases. Results for TTL showed
no relevant differences in diseased and non-diseased
study participants. With regards to the inflammatory sta-
tus, subjects with and without subclinical inflammation
(CRP ≤3 vs. >3 mg/L) had almost identically strong asso-
ciations of d-ROMs levels with all-cause, CVD and can-
cer mortality, but the association of TTL with all-cause
and CVD mortality was significant only in subjects with
subclinical inflammation. Finally, although the associa-
tions of d-ROMs levels and TTL were weaker with events
occurring later in the follow-up, even associations with
events that occurred 4–6 years after baseline were statisti-
cally significant in the meta-analysis of the four cohorts.
All heterogeneity statistics for meta-analyses of longitu-
dinal analyses of the included four cohorts indicated low,
statistically non-significant levels of heterogeneity.
Discussion
Principal findings
In this meta-analysis of four population-based cohort
studies from Central and Eastern Europe, the serum oxi-
dative stress markers d-ROMs and TTL were associated
with all-cause mortality independently from each other
and independently from other risk factors for mortality,
including inflammation. d-ROMs levels were strongly
associated with all major causes of death, whereas TTL
were only associated with CVD mortality. The strength
of the association of TTL with CVD mortality increased
with age of the participants and was additive to the ex-
cess risk of d-ROMs levels. Especially, individuals with
very high d-ROMs levels seem to have a particularly
high risk for short-term mortality (corresponding to 4-
to 5-fold increased mortality from CVD and cancer).
Strength and weaknesses
This meta-analysis of individual participant data has sev-
eral strengths, including the variety of cohorts from Cen-
tral and Eastern Europe, the broad age range from 45–84
years, the overall large size enabling subgroup and cause-
specific mortality analyses, almost complete registry-based
mortality follow-ups, the common statistical analysis strat-
egy, and the detailed assessment of all major risk factors
for mortality enabling a comprehensive correction for
confounding.
However, due to the observational nature of the study,
confounding cannot be totally excluded and any causal in-
ference has to be made with caution. For example, in order
to adjust for inflammation, we used the general inflamma-
tory biomarker CRP, whereas a set of more specific inflam-
matory markers (e.g. interleukins) could have further
reduced any potential confounding by inflammation. Fur-
thermore, the study results cannot be generalized to non-
Caucasians. A further limitation is that we did not use re-
peated d-ROMs and TTL measurements during follow-up
which could have led to stronger effect estimates because
effect estimates were weaker for events that occurred later
during follow-up. However, we were able to show that asso-
ciations of d-ROMs levels and TTL remained statistically
significant with deaths that occurred 5–6 years after base-
line, showing their predictive value not only for short-term
mortality but also for up to 6-year mortality. Nevertheless,
studies with repeated measures and even longer follow-up
would be helpful to shed more light on the predictive value
of d-ROMs levels and TTL for long-term mortality. Finally,
Table 4 Joint risk assessment for cardiovascular disease mortality by derivatives of reactive oxygen metabolites (d-ROMs) levels and
total thiol levels (TTL)
High oxidative stress by Proportion of population ncases RR (95 % CI)
c
d-ROMsa TTLb ESTHER HAPIEE controls ESTHER + HAPIEE ESTHER + HAPIEE
No No 59 % 49 % 227 Ref
No Yes 18 % 25 % 108 1.34 (0.91–1.97)
Yes No 16 % 18 % 155 1.72 (1.27–2.32)*
Yes Yes 7 % 9 % 70 2.47 (1.58–3.98)*
*Statistically significant (P <0.05)
ad-ROMs levels >400 Carr U
bLowest quartile of TTL in the different cohorts, i.e. ESTHER <281.57 μmol/L; HAPIEE Poland cases and eligible controls <464 μmol/L; HAPIEE Czech Republic cases
and eligible controls <371 μmol/L; HAPIEE Lithuania cases and eligible controls <283 μmol/L
cMeta-analysis of HAPIEE Poland, Czech Republic, Lithuania and ESTHER study. Model controlled for age, sex, education, BMI, smoking status, alcohol consumption
and vigorous physical activity
CI, Confidence interval; ncases, Incident case numbers; RR, Risk ratio
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Table 5 Association of derivatives of reactive oxygen metabolites (d-ROMs) levels and total thiol levels (TTL) with all-cause and disease
specific mortality stratified by cohort/country, sex, age, history of myocardial infarction, history of cancer, inflammatory status and time-point
of event during follow-up
Outcome Stratum ncases Increase of d-ROMs by 1 SD
a Decrease of TTL by 1 SDb
RR (95 % CI)c RR (95 % CI)c
Stratified by cohort/country
All-cause mortality HAPIEE Poland 525 1.29 (1.14–1.46)* 1.14 (1.01–1.28)*
HAPIEE Czech Republic 518 1.33 (1.17–1.51)* 1.05 (0.93–1.19)
HAPIEE Lithuania 390 1.47 (1.25–1.71)* 1.31 (1.10–1.57)*
ESTHER (Germany) 269 1.33 (1.18–1.49)* 1.31 (1.15–1.48)*
CVD mortality HAPIEE Poland 165 1.54 (1.21–1.95)* 1.22 (0.98–1.53)
HAPIEE Czech Republic 189 1.56 (1.22–2.00)* 1.25 (0.99–1.56)
HAPIEE Lithuania 155 1.40 (1.06–1.85)* 1.48 (1.06–2.06)*
ESTHER (Germany) 51 1.24 (0.94–1.63) 1.39 (1.06–1.84)*
Cancer mortality HAPIEE Poland 235 1.17 (0.98–1.41) 1.06 (0.89–1.26)
HAPIEE Czech Republic 235 1.36 (1.13–1.63)* 0.95 (0.79–1.14)
HAPIEE Lithuania 158 1.60 (1.25–2.04)* 1.18 (0.89–1.55)
ESTHER (Germany) 74 1.40 (1.13–1.74)* 1.21 (0.96–1.53)
Stratified by age
All-cause mortality 45 to <60 yearsd 423 1.23 (1.04–1.45)* 1.16 (1.01–1.34)*
60 to <70 years 933 1.39 (1.27–1.53)* 1.16 (1.05–1.29)*
70 to <85 yearse, f 303 1.33 (1.17–1.52)* 1.35 (1.18–1.55)*
CVD mortality 45 to <60 yearsd 126 1.42 (1.01–2.00)* 1.24 (0.91–1.69)
60 to <70 yearsd 322 1.64 (1.35–2.00)* 1.31 (1.09–1.56)*
70 to <85 yearse, f 90 1.28 (0.97–1.69) 1.65 (1.22–2.24)*
Cancer mortality 45 to <60 yearsd 177 1.21 (0.81–1.81) 1.20 (0.96–1.50)
60 to <70 yearsd 392 1.41 (1.21–1.64)* 1.02 (0.86–1.21)
70 to <85 yearse, f 94 1.46 (1.13–1.87)* 1.17 (0.89–1.52)
Stratified by sex
All-cause mortality Women 587 1.28 (1.13–1.44)* 1.25 (1.05–1.50)*
Men 1115 1.40 (1.29–1.53)* 1.18 (1.08–1.28)*
CVD mortality Womend 157 1.42 (1.08–1.87)* 1.28 (0.98–1.69)
Men 385 1.50 (1.27–1.76)* 1.33 (1.13–1.56)*
Cancer mortality Women 257 1.31 (1.05–1.65)* 1.16 (0.96–1.40)
Men 445 1.39 (1.21–1.59)* 1.06 (0.93–1.21)
Stratified by history of MI
All-cause mortality No history of MI 1286 1.33 (1.22–1.41)* 1.17 (1.04–2.61)*
History of MIg 375 1.39 (1.17;1.65 )* 1.19 (0.97–1.63)
CVD mortality No history of MI 379 1.35 (1.14–1.57)* 1.22 (1.04–1.43)*
History of MId, g 165 1.45 (1.04–2.02)* 1.19 (0.88–1.61)
Stratified by history of cancer
All-cause mortality No history of cancer 1382 1.32 (1.23–1.42)* 1.16 (1.05–1.29)*
History of cancerg 257 1.49 (1.24–1.77)* 1.24 (1.00–1.54)*
Cancer mortality No history of cancer 533 1.29 (1.15–1.45)* 1.01 (0.89–1.14)
History of cancerg 169 1.53 (1.19–1.97)* 1.16 (0.91–1.47)
Stratified by inflammatory status
All-cause mortality CRP ≤3 mg/L 933 1.19 (1.08–1.31)* 1.12 (0.97–1.30)
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we would like to state that the total thiol/total disulfide ra-
tio would have been a better indicator of the oxidative sta-
tus than TTL alone. However, disulfides were not
measured because, to date, a reliable and time-efficient la-
boratory method for large-scale measurements is not
available.
Comparison with other studies
This study with up to 8-year follow-up is a major im-
provement compared to the first analysis of the ESTHER
study, with 3.3 years of follow-up [10]. In the current
analysis, the ESTHER follow-up was extended to 5 years,
and the sample size with d-ROMs and TTL measure-
ments was increased from 2,932 to 4,027 subjects. The
increase in statistical power was even larger by the
addition of the HAPIEE cohorts with their high case
numbers. The results for all-cause mortality were simi-
lar to those of the first ESTHER analysis and were cor-
roborated by the results from HAPIEE Poland, Czech
Republic, and Lithuania. As in the earlier analysis, we
observed attenuations of the effect estimates for TTL
and d-ROMs levels after adjustment for history of
chronic diseases and CRP but the results remained sta-
tistically significant for both TTL and d-ROMs levels,
indicating that both markers are risk factors for mortal-
ity independent of the presence of common diseases
and a high inflammatory status.
With the large numbers of cases in the HAPIEE cohorts,
it was possible, for the first time, to address cause-specific
mortality. Interestingly, high d-ROMs levels seem to be a
general risk factor for all major causes of death, whereas
the weaker association of TTL with all-cause mortality
seems to be specific to CVD mortality. No other compar-
able studies have assessed the association of oxidative stress
markers with cause-specific mortality in the general popu-
lation thus far. For all-cause mortality, several population-
based cohort studies restricted to older adults (≥65 years)
applied other oxidative stress markers and observed signifi-
cant associations of the oxidative DNA damage marker
urinary 8-iso-prostaglandin F2α [24], the anti-oxidant nutri-
ent selenium [25], and the protein oxidation marker protein
carbonyls [26] with total mortality. These oxidative stress
markers do not measure hydrogen peroxides or free thiol
groups, as the d-ROMs and TTL assays, respectively, do.
The fact that different assays for the common concept of
oxidative stress lead to similar findings provides support for
the free radical/oxidative stress theory of ageing. This evi-
dence is further supported by studies with transgenic and
knockout mice, which propose oxidative stress biomarkers
as risk factors for premature death [5].
Interpretation of the findings
According to the free radical/oxidative stress theory of age-
ing, an increased production of ROS promotes cell senes-
cence and an increased apoptosis rate [4, 5]. Oxidative
stress occurs when ROS cannot be balanced by anti-
oxidative capacities in cells and tissues. In our study, d-
ROMs levels and TTL were virtually uncorrelated and
were independently associated with CVD mortality. This
implies that oxidative and anti-oxidative molecules in
blood may influence each other less than one would
expect.
Table 5 Association of derivatives of reactive oxygen metabolites (d-ROMs) levels and total thiol levels (TTL) with all-cause and disease
specific mortality stratified by cohort/country, sex, age, history of myocardial infarction, history of cancer, inflammatory status and time-point
of event during follow-up (Continued)
CRP >3 mg/L 769 1.26 (1.15–1.38)* 1.16 (1.05–1.28)*
CVD mortality CRP ≤3 mg/Ld 265 1.26 (1.00–1.58)* 1.10 (0.90–1.35)
CRP >3 mg/L 275 1.28 (1.07–1.54)* 1.22 (1.01–1.48)*
Cancer mortality CRP ≤3 mg/L 394 1.22 (1.04–1.43)* 1.06 (0.90–1.26)
CRP >3 mg/L 308 1.27 (1.10–1.46)* 1.07 (0.91–1.26)
Stratified by time-point of event during follow-up
All-cause mortality ≤ year 2 419 1.46 (1.29–1.66)* 1.29 (1.11–1.50)*
> year 2 to≤ year 4 597 1.31 (1.17–1.46)* 1.18 (1.06–1.33)*
> year 4 to≤ year 6 433 1.25 (1.09–1.43)* 1.17 (1.02–1.33)*
*Statistically significant (P <0.05)
a1 SD of d-ROMs levels equal to 81.1, 89.6, 70.5, and 71.9 Carr U in the HAPIEE Poland, Czech Republic, Lithuania, and ESTHER study, respectively
b1 SD of TTL equals 79.5, 69.1, 74.1, and 75.3 μmol/L in the HAPIEE Poland, Czech Republic, Lithuania, and ESTHER study, respectively
cMeta-analysis of HAPIEE Poland, Czech Republic, Lithuania, and ESTHER study if not stated otherwise. Model controlled for age, sex, education, BMI, smoking
status, alcohol consumption, vigorous physical activity, and the other oxidative stress marker (i.e. TTL or d-ROMs)
dMeta-analyses without the ESTHER study because too few events (<25) were observed in this category in this study
eMeta-analyses without the HAPIEE Poland study because too few events (<25) were observed in this category in this study
f Meta-analyses without the HAPIEE Czech Republic study because too few events (<25) were observed in this category in this study
gOne instead of two matched controls due to a shortage of potential controls in this category in the HAPIEE cohorts
CVD, Cardiovascular disease; CI, Confidence interval; CRP, C-reactive protein; MI, Myocardial infarction; ncases, Incident case numbers; RR, Risk ratio; SD,
Standard deviation
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Some insights on different mechanisms of action by d-
ROMs and TTL can be drawn from their diverging cross-
sectional associations with baseline characteristics. The
only agreement was found in the fact that female sex and
increasing CRP levels were strongly associated with higher
odds of both high d-ROMs levels and low TTL. This is as
expected since ROS can provoke and potentiate inflamma-
tory processes and vice versa [3]. In addition, previous
studies have already reported correlations of oxidative
stress biomarkers with female hormones [27]. Besides that,
high oxidative stress by d-ROMs levels was associated with
smoking, increasing total cholesterol, increasing HDL
cholesterol, and a history of hypertension, MI or cancer,
whereas high oxidative stress by TTL was associated with
increasing age, increasing BMI, and renal impairment. It
appears that smoking and major chronic diseases tend to
be related to d-ROMs levels, whereas classical factors in-
creasing with age (i.e. BMI, renal impairment, increasing
subclinical inflammation) are rather related to TTL. Inter-
estingly, the association of TTL with CVD mortality in-
creased with age of the participants whereas the association
of d-ROMs levels with mortality outcomes was independ-
ent from participant age.
These results suggest that pro-oxidative processes re-
main stable in middle and older age (with smokers and
subjects with diseases having higher oxidative stress) and
can be hazardous throughout the adult life-time (espe-
cially because of the association of d-ROMs levels with
cancer), whereas anti-oxidative capacities in blood de-
crease with age (as shown by Pandey et al. [28]), which be-
comes problematic when they can no longer outbalance
pro-oxidative situations at older age (especially after the
age of 70 years in our cohorts). It is known that, at the
end of life, protein structures essential for protein function
and thiol-based redox signaling are increasingly less well
maintained, which can contribute to organ function failure
and ultimately death of the organism [28, 29]. Moreover,
oxidative processes play an important role in the develop-
ment and rupture of atherosclerotic plaques in blood ves-
sels [30, 31], which may be facilitated by low TTL. This
may explain why TTL was specifically associated with
CVD mortality in older adults.
The fact that TTL was not associated with cancer mor-
tality may suggest that this marker gives insights into the
oxidative status of blood vessels but not necessarily into
the oxidative status of cells (which could degenerate to
cancer cells by oxidative DNA damage and other oxidative
pathways [32]). On the contrary, d-ROMs serum levels
were associated with cancer mortality, implying that they
may give information about the ROS concentration in
cells. This is not unexpected because it is known that hy-
droperoxides, which are the ROS class being detected by
the d-ROMs assay, can be transported from cells to blood
vessels to decrease the oxidative potential of a cell.
Clinical implications and future research
The presented analyses focused on mortality. Therefore,
future studies should shed light on the associations of d-
ROMs levels and TTL with major underlying causes of
mortality. Only one large-scale application of the d-ROMs
assay for the outcome “incident colorectal cancer” is avail-
able so far, reporting a strong association with an adjusted
incidence rate ratio for comparison of top and bottom d-
ROMs tertile of 1.91 (95 % CI, 1.47–2.48) [23]. However,
there is a large number of diseases with a potential oxida-
tive stress component that should be addressed in future
studies (e.g. CVD, neoplasms, type 2 diabetes mellitus,
osteoarthritis, autoimmune diseases, and neurologic dis-
eases) [32]. If relationships could be established, d-ROMs
levels and TTL could be used as prognostic markers for
such diseases to guide early prevention. In particular,
CVD risk prediction in the elderly is a promising target
for d-ROMs and TTL measurements because subjects
with high d-ROMs levels and low TTL had a 2.5-fold rela-
tive risk for CVD mortality compared to subjects with low
d-ROMs levels and high TTL in our study. Such a strong
effect estimate is remarkable, particularly as it was ad-
justed for all major established cardiovascular risk factors.
Especially in the elderly (≥65 years), in whom traditional
cardiovascular risk factors have limited prognostic value
[33], oxidative stress markers could be a major corner-
stone for cardiovascular risk scores. With control of the
oxidative status, frequently mentioned in the media as an
important aspect for healthy ageing (mainly to advertise
functional foods), there is an increasing demand for test-
ing of the oxidative status in the primary care setting. It is
important that this field is evidence-based because, as out-
lined in the introduction, measuring oxidative stress is
complex. This paper has further elaborated the evidence
that d-ROMs and TTL assays do measure redox com-
pounds, which can be relevant for the prediction of mor-
tality in middle-aged and older Caucasian individuals.
However, knowing the oxidative status is worth nothing
without effective therapies against it. Anti-oxidant supple-
ments have failed to show a reduction of mortality in ran-
domized controlled trials or even increased it [34, 35].
However, this does not discredit the free radical/oxidative
stress theory of ageing because it is the proximity of the
mitochondrial complex I ROS generating site to the mito-
chondrial DNA that matters most for ageing [36]. The
concentration of anti-oxidants elsewhere is irrelevant.
Therefore, since the millennium, treatments targeted
against the main enzyme generating ROS, nicotinamide
adenine dinucleotide phosphate oxidase (NOX), are be-
ing developed with promising results in vivo [37]. How-
ever, more research is needed towards isoform-specific
NOX-inhibitors but there is optimism that such drugs
will be available in the near future [38]. Furthermore,
there is still large interest in resveratrol, the active
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polyphenol present in red wine, which could be cardio-
protective, anti-carcinogenic, and anti-inflammatory by
potent antioxidant activities [39]. The strong associa-
tions of the oxidative stress markers d-ROMs and TTL
with mortality in this study show the high potential of
anti-oxidative drugs regarding a prolongation of the
healthy life-span. Therefore, we can recommend meas-
urement of d-ROMs levels and TTL in clinical trials as
surrogate parameters of oxidative stress.
Such clinical trials could also address life-style inter-
ventions. It is possible that life-style changes, including
smoking cessation, increasing physical activity, weight
loss, and a diet favouring nutrients with natural anti-
oxidants (e.g. vegetables and fruits) could have
favourable effects on oxidative stress marker levels [40].
It is possible that the positive effects of these life-style
changes on general health originate in part from their
positive effects on redox homeostasis.
Before d-ROMs levels and TTL could be applied as
prognostic markers in clinical trials and clinical practice,
questions of international standardization of the TTL
assay and cut-off values for clinically-relevantly values
for both assays should be solved. Although the d-ROMs
assay is standardized and suggested cut-offs were suit-
able for risk stratification in our studies, future studies
should elucidate whether sex-specific cut-offs could be
better since women have higher d-ROMs levels than
men but lower mortality.
Conclusions
We conclude that this meta-analysis of four population-
based cohort studies adds epidemiological evidence to
the free radical/oxidative stress theory of ageing. Both d-
ROMs levels and TTL were strongly associated with all-
cause and CVD mortality and d-ROMs levels were add-
itionally strongly associated with cancer mortality. Note-
worthy, individuals with very high d-ROMs levels seem
to have a particularly increased risk of short-term mor-
tality, which was approximately 4- to 5-fold increased
for CVD and cancer mortality. High d-ROMs levels and
low TTL could be markers of different redox pathways
associated with pre-mature mortality. Both markers may
be useful for cardiovascular risk prediction in the elderly
and as surrogate endpoints for clinical trials aiming to
evaluate life-style interventions and novel drugs for
redox homeostasis.
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